133
Participants
Start Date
December 31, 2013
Primary Completion Date
December 31, 2016
Study Completion Date
December 31, 2016
Anlotinib
Anlotinib p.o. qd
Sunitinib maleate
Sunitinib 50 mg p.o. qd
Peking Union Medical College Hospital, Beijing
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing
China General Hospital of Shenyang Military Region, Shenyang
Liaoning Province Tumor Hospital, Shenyang
Jilin Cancer Hospital, Changchun
Harbin medical university affiliated tumor hospital, Haerbin
Cancer Hospital of Fudan University, Shanghai
The 81st Hospital of Chinese PLA, Nanjing
Qilu Hospital,Shandong University, Jinan
Tianjin Medical University Cancer Hospital, Tianjin
Chongqing Cancer Hospital, Chongqing
Sun Yat-Sen University Cancer Center, Guangzhou
Guangxi medical university affiliated tumor hospital, Nanning
West China Hospital,Sichuan University, Chengdu
Gansu Province Tumor Hospital, Lanzhou
Lead Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
INDUSTRY